Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CDC Expands Vaccine Distribution Partnership With McKesson
McKesson has reported that its current partnership with the Centers for Disease Control and Prevention (CDC) has been expanded to include preparations for H1N1 flu vaccine distribution. CDC
McKesson has reported that its current partnership with the Centers for Disease Control and Prevention (CDC) has been expanded to include preparations for H1N1 flu vaccine distribution. CDC
Array BioPharma (Array) has reported revenue of $5.5m for the fourth quarter of fiscal 2009, compared to $6.1m for the same period in fiscal 2008. The company reported
Depomed’s phase 1 pharmacokinetic study for DM-1992 has shown positive results, with an extended coverage above levodopa’s efficacious threshold and also extended the time to peak levodopa concentration
Taro Pharmaceutical has provided preliminary results for the six months ended June 30, 2009. The company estimates net sales of $181.7m compared to $166.2m in the same period
FDA has approved Actelion’s supplemental New Drug Application (sNDA) for Tracleer (bosentan) to treat patients with mildly symptomatic WHO Functional Class II (FC II) pulmonary arterial hypertension (PAH).
YM BioSciences (YM) has received a license from the US Department of the Treasury’s Office of Foreign Assets Control (OFAC), to further develop its lead product – nimotuzumab
CytRx has reported a net loss of $2.2m, or $0.02 per share for the second quarter ended June 30, 2009, compared with a net loss of $5.8m, or
Dendreon has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Georgia. The company expects to manufacture PROVENGE (sipuleucel-T),
FDA has approved Actelion’s new 20mcg/ml formulation of Ventavis as a therapy for New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). The new increased
Patheon’s Manati solid dose manufacturing facility in Puerto Rico has received regulatory approval from the European Medicines Agency (EMEA), following the completion of inspection by the Medical Products